News Releases

19 Oct '2022
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated   in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62 .5% and   37 .5
03 Jun '2022
MONMOUTH JUNCTION, N.J. , June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it has filed a Certificate of Amendment to the Amended and
26 May '2022
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® ( pembrolizumab) Updated data continue to show disease control rate of 67% in Part C, with ADXS-503
08 Apr '2022
ADXS-PSA in combination with KEYTRUDA ® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated
28 Mar '2022
On March 28, 2022, we issued a Supplemental Proxy Statement, which includes additional information about how to vote regarding Proposal No. 1 to be voted on at the Special Meeting of Stockholders scheduled for March 31, 2022. The Supplemental Proxy Statement issued on March 28, 2022 is located
Displaying 1 - 10 of 13